A
Actinium Pharmaceuticals, Inc. (ATNM)
ASE – Real Time Price. Currency in USD
1.30
-0.04 (-2.99%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
1.30
-0.04 (-2.99%)
At close: May 12, 2026, 4:00 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 6.20 | 6.05 | 10 | |
| Quick ratio | 6.20 | 5.63 | 10 | |
| Debt to Equity | 0.22 | 0.30 | 8.0 | |
| Debt to Assets | 0.03 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 930K | 81K | N/A | 90K | 90K |
| Gross Profit | 231K | -709K | -811K | -731K | -731K |
| Operating Income | -34M | -52M | -42M | -36M | -36M |
| Net Income | -33M | -49M | -38M | -34M | -34M |
| EBITDA | -34M | -51M | -41M | -35M | -35M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 53.92 | 5.5 |
| Next quarter | N/A | -6.82 | 1.0 |
| Current year | -100 | 16.74 | 5.0 |
| Next year | N/A | 3.03 | 2.5 |
| Weighted average score | 3.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -99.99 | -15.76 | -18.74 | 14.74 | 2.8 |
| Y/Y | 999 | 10.7 | 9.52 | 6.23 | 7.0 |
| 3y average | 269.24 | -4.92 | 3.73 | -205.97 | 4.0 |
| 5y average | 357.61 | -11.9 | 6.29 | -94.9 | 4.3 |
| Weighted average score | 4.5 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $48.0M significantly exceed its total debt $1.7M, ensuring strong financial flexibility
Total current assets $49.4M exceed Total current liabilities $8.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$5.4M limits the company's ability to reinvest or pay down debt